GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Debt-to-Equity

Surface Oncology (Surface Oncology) Debt-to-Equity : 0.19 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Debt-to-Equity?

Surface Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $9.49 Mil. Surface Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Surface Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $49.18 Mil. Surface Oncology's debt to equity for the quarter that ended in Jun. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Surface Oncology's Debt-to-Equity or its related term are showing as below:

SURF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.19   Med: 0.42   Max: 0.73
Current: 0.19

During the past 7 years, the highest Debt-to-Equity Ratio of Surface Oncology was 0.73. The lowest was 0.19. And the median was 0.42.

SURF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs SURF: 0.19

Surface Oncology Debt-to-Equity Historical Data

The historical data trend for Surface Oncology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Debt-to-Equity Chart

Surface Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial - 0.44 0.32 0.48 0.60

Surface Oncology Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.50 0.60 0.73 0.19

Competitive Comparison of Surface Oncology's Debt-to-Equity

For the Biotechnology subindustry, Surface Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surface Oncology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surface Oncology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Surface Oncology's Debt-to-Equity falls into.



Surface Oncology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Surface Oncology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Surface Oncology's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surface Oncology  (NAS:SURF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Surface Oncology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Surface Oncology (Surface Oncology) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
Chandra Adams officer: Deputy GC SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill officer: Chief Medical Officer
Jessica Fees officer: See Remarks C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross officer: Chief Medical Officer C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath officer: Chief Business Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella officer: Chief Scientific Officer 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn director C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey director C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater director, officer: Chief Executive Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p. 10 percent owner 46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc 10 percent owner 56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118